{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:23:12Z","timestamp":1795173792621,"version":"4.10.3"},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"18","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K23 CA190849-01A1"],"award-info":[{"award-number":["K23 CA190849-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1UM1CA186688"],"award-info":[{"award-number":["1UM1CA186688"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA047904"],"award-info":[{"award-number":["P30 CA047904"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["UM1 CA099168"],"award-info":[{"award-number":["UM1 CA099168"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>MEK inhibition is of interest in cancer drug development, but clinical activity in metastatic colorectal cancer (mCRC) has been limited. Preclinical studies demonstrated Wnt pathway overexpression in KRAS-mutant cell lines resistant to the MEK inhibitor, selumetinib. The combination of selumetinib and cyclosporin A, a noncanonical Wnt pathway modulator, demonstrated antitumor activity in mCRC patient-derived xenografts. To translate these results, we conducted a NCI Cancer Therapy Evaluation Program\u2013approved multicenter phase I\/IB trial (NCT02188264) of the combination of selumetinib and cyclosporin A. Patients with advanced solid malignancies were treated with the combination of oral selumetinib and cyclosporin A in the dose escalation phase, followed by an expansion cohort of irinotecan and oxaliplatin-refractory mCRC. The expansion cohort utilized a single-agent selumetinib \u201crun-in\u201d to evaluate FZD2 biomarker upregulation and KRAS-WT and KRAS-MT stratification to identify any potential predictors of efficacy. Twenty and 19 patients were enrolled in dose escalation and expansion phases, respectively. The most common adverse events and grade 3\/4 toxicities were rash, hypertension, and edema. Three dose-limiting toxicities (grade 3 hypertension, rash, and increased creatinine) were reported. The MTD was selumetinib 75 mg twice daily and cyclosporin A 2 mg\/kg twice daily on a 28-day cycle. KRAS stratification did not identify any differences in response between KRAS-WT and KRAS-MT cancers. Two partial responses, 18 stable disease, and 10 progressive disease responses were observed. Combination selumetinib and cyclosporin A is well tolerated, with evidence of activity in mCRC. Future strategies for concept development include identifying better predictors of efficacy and improved Wnt pathway modulation.<\/jats:p>\n               <jats:p>Significance: These findings translate preclinical studies combining selumetinib and cyclosporin into a phase I first-in-human clinical trial of such a combination in patients with advanced solid malignancies. Cancer Res; 78(18); 5398\u2013407. \u00a92018 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-18-0316","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T17:40:56Z","timestamp":1532454056000},"page":"5398-5407","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer"],"prefix":"10.1158","volume":"78","author":[{"given":"Anuradha","family":"Krishnamurthy","sequence":"first","affiliation":[{"name":"1University of Colorado, Denver, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[{"name":"2MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Noonan","sequence":"additional","affiliation":[{"name":"3Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Mehnert","sequence":"additional","affiliation":[{"name":"4Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert C.","family":"Lockhart","sequence":"additional","affiliation":[{"name":"5Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Leong","sequence":"additional","affiliation":[{"name":"1University of Colorado, Denver, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Capasso","sequence":"additional","affiliation":[{"name":"1University of Colorado, Denver, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N.","family":"Stein","sequence":"additional","affiliation":[{"name":"4Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna K.","family":"Sanoff","sequence":"additional","affiliation":[{"name":"6University of North Carolina, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Lee","sequence":"additional","affiliation":[{"name":"7University of Pittsburgh, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Hansen","sequence":"additional","affiliation":[{"name":"8Princess Margaret Hospital, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Malhotra","sequence":"additional","affiliation":[{"name":"4Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rippke","sequence":"additional","affiliation":[{"name":"1University of Colorado, Denver, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Gustafson","sequence":"additional","affiliation":[{"name":"9Colorado State University, Denver, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Pitts","sequence":"additional","affiliation":[{"name":"1University of Colorado, Denver, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Ellison","sequence":"additional","affiliation":[{"name":"1University of Colorado, Denver, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Lindsey","family":"Davis","sequence":"additional","affiliation":[{"name":"1University of Colorado, Denver, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wells A.","family":"Messersmith","sequence":"additional","affiliation":[{"name":"1University of Colorado, Denver, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Gail","family":"Eckhardt","sequence":"additional","affiliation":[{"name":"1University of Colorado, Denver, Colorado."},{"name":"10University of Texas at Austin Dell Medical School, LIVESTRONG Cancer Institutes, Austin, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Lieu","sequence":"additional","affiliation":[{"name":"1University of Colorado, Denver, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2018,9,14]]},"reference":[{"key":"2022061706040247600_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","article-title":"Global patterns and trends in colorectal cancer incidence and mortality","volume":"66","author":"Arnold","year":"2017","journal-title":"Gut"},{"key":"2022061706040247600_bib2","article-title":"Cancer Stat Facts: colon and rectum cancer","author":"Surveillance Epidemiology and End Results Program"},{"key":"2022061706040247600_bib3","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"2022061706040247600_bib4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2022061706040247600_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.12.001","article-title":"Cancer resistance to therapies against the EGFR-RAS-RAF pathway: the role of MEK","volume":"53","author":"Martinelli","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2022061706040247600_bib6","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1158\/1078-0432.CCR-12-3140","article-title":"Rational combination of a MEK inhibitor, selumetinib, and the Wnt\/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer","volume":"19","author":"Spreafico","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022061706040247600_bib7","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022061706040247600_bib8","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"2022061706040247600_bib9","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022061706040247600_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"2022061706040247600_bib11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"2022061706040247600_bib12","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"2022061706040247600_bib13","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","article-title":"Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study","volume":"15","author":"Ribas","year":"2014","journal-title":"Lancet Oncol"},{"key":"2022061706040247600_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061706040247600_bib15","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1002\/ijc.24604","article-title":"Intrinsic resistance to the MEK1\/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1\/2 signalling and\/or strong PI3K signalling in colorectal cancer cell lines","volume":"125","author":"Balmanno","year":"2009","journal-title":"Int J Cancer"},{"key":"2022061706040247600_bib16","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022061706040247600_bib17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10637-010-9392-8","article-title":"A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1\/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens","volume":"29","author":"Bennouna","year":"2011","journal-title":"Invest New Drugs"},{"key":"2022061706040247600_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-014-2609-3","article-title":"Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer","volume":"75","author":"Hochster","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022061706040247600_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s10637-015-0314-7","article-title":"A phase I study of selumetinib (AZD6244\/ARRY-142866), a MEK1\/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer","volume":"34","author":"Deming","year":"2016","journal-title":"Invest New Drugs"},{"key":"2022061706040247600_bib20","doi-asserted-by":"crossref","first-page":"C511","DOI":"10.1152\/ajpcell.00117.2015","article-title":"Targeting Wnt signaling in colorectal cancer. A review in the theme: cell signaling: proteins, pathways and mechanisms","volume":"309","author":"Novellasdemunt","year":"2015","journal-title":"Am J Physiol Cell Physiol"},{"key":"2022061706040247600_bib21","doi-asserted-by":"crossref","first-page":":116\u201336","DOI":"10.1038\/labinvest.2015.144","article-title":"The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies","volume":"96","author":"Yang","year":"2016","journal-title":"Lab Invest"},{"key":"2022061706040247600_bib22","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1158\/1535-7163.MCT-10-0376","article-title":"Identification of predictive markers of response to the MEK1\/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer","volume":"9","author":"Tentler","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2022061706040247600_bib23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","article-title":"Wnt\/Ca2+\/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl","volume":"18","author":"Gregory","year":"2010","journal-title":"Cancer Cell"},{"key":"2022061706040247600_bib24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4049\/jimmunol.1102297","article-title":"Wnt5a is secreted by follicular dendritic cells to protect germinal center B cells via Wnt\/Ca2+\/NFAT\/NF-kappaB-B cell lymphoma 6 signaling","volume":"188","author":"Kim","year":"2012","journal-title":"J Immunol"},{"key":"2022061706040247600_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"2022061706040247600_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/vde.12222","article-title":"Comparison of the stability and pharmacokinetics in dogs of modified ciclosporin capsules stored at -20 degrees C and room temperature","volume":"26","author":"Bachtel","year":"2015","journal-title":"Vet Dermatol"},{"key":"2022061706040247600_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00280-010-1323-z","article-title":"Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice","volume":"67","author":"Denton","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022061706040247600_bib28","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1523-1755.2005.00472.x","article-title":"Cellular mechanisms of vascular injury mediated by calcineurin inhibitors","volume":"68","author":"Lamas","year":"2005","journal-title":"Kidney Int"},{"key":"2022061706040247600_bib29","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/ki.1993.101","article-title":"Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion","volume":"43","author":"Ruggenenti","year":"1993","journal-title":"Kidney Int"},{"key":"2022061706040247600_bib30","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1078-0432.CCR-09-2483","article-title":"The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer","volume":"16","author":"Banerji","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022061706040247600_bib31","article-title":"NEORAL: Prescribing Information","author":"Novartis","year":"2009"},{"key":"2022061706040247600_bib32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/13543784.2012.665871","article-title":"Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma","volume":"21","author":"Patel","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"2022061706040247600_bib33","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1200\/JCO.2004.01.185","article-title":"Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer","volume":"22","author":"Rinehart","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/18\/5398\/2773480\/5398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/18\/5398\/2773480\/5398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T17:12:37Z","timestamp":1655485957000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/78\/18\/5398\/631842\/Phase-Ib-Results-of-the-Rational-Combination-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,14]]},"references-count":33,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2018,9,14]]},"published-print":{"date-parts":[[2018,9,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-18-0316","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,14]]}}}